Lymphoma down arrow


Hodgkin Lymphoma





Most relapses occur in the first 3 years after therapy.

50 - 80% of patients treated with initial RT alone were salvaged after relapse with combination chemotherapy.

The prognosis of Hodgkin lymphoma relapse is directly related to duration of initial response.

  • Progression during induction therapy
    • Associated with a 5-year disease-free survival of almost zero.
  • Relapse within 12 months of completion of therapy
    • Associated with a 5-year disease-free survival 20%.
  • Relapse  occurring 12 months or greater
    • Associated with survival rates of 20-50% with standard chemotherapy.


High-dose therapy and BM autografting is the treatment of choice for patients with relapsed or refractory Hodgkin lymphoma.


Cytoreductive Chemotherapy:

Conventional cytoreductive (re-induction) chemotherapy is generally used prior to high-dose therapy.

ICE chemotherapy is usually employed for cytoreduction


I = Ifosfamide

C = Carboplatin

E = Etoposide

G-CSF is used for supportive care.

High-dose therapy is most effective for patients who enter with minimal or sensitive disease - minimal disease status at the time of transplant is a major predictor of improved event free survival (EFS).







Back to top